Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO1993021992) LASER TREATMENT
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

Claims

1. A method of disinfecting or sterilising tissues of the oral cavity or a wound or lesion in the oral cavity which method comprises applying a photosensitising compound to said tissues, wound or lesion and irradiating said tissues, wound or lesion with laser light at a wavelength absorbed by said photosensitising compound.

2. Use of a photosensitising compound in the manufacture of a medicament for use in disinfecting or sterilising tissues of the oral cavity or a wound or lesion in the oral cavity by
(a) contacting the tissues, wound or lesion
with the photosensitising compound such
that any disease-related microbes in the
tissue, wound or lesion take up the
photosensitising compound and
(b) irradiating the tissues, wound or lesion
with laser light at a wavelength absorbed
by the photosensitising compound.

3. A method according to claim 1 or use according to claim 2 for
(i) destruction of disease-related microbes
in a periodontal pocket in order to treat
chronic periodontitis;

(ii) destruction of disease-related microbes
in the region between the tooth and
gingiva in order to treat or prevent
inflammatory periodontal diseases;
(iϋ) disinfection or sterilisation of drilled- out carious lesions prior to filling;
(iv) destruction of cariogenic microbes on a
tooth surface in order to treat or
prevent dental caries;
(v) disinfection or sterilisation of dental
or gingival tissues in dental surgical
procedures and
(vi) treatment of oral candidiasis in AIDS
patients, immunocompromised patients or
patients with denture stomatitis.

4. A method or use according to any preceding claim wherein the photosensitiser is selected from arianor steel blue, toluidine blue O, crystal violet, methylene blue, azure blue cert, azure B chloride, azure 2, azure A chloride, azure B tetrafluoroborate, thionin, azure A eosinate, azure B eosinate, azure mix sice, azure II eosinate, haematoporphyrin HCl, haematoporphyrin ester, aluminium disulphonated phthalocyanine and chlorins.

5. A method or use according to any preceding claim wherein the laser light is from a helium neon gas laser or gallium arsenide laser.

6. A method or use according to any preceding claim wherein the laser has a power of from 1 to" lOOmW and a beam diameter of from 1 to 10mm.

7. A method or use according to any preceding claim wherein the duration of laser irradiation is from one second to five minutes and the light dose is from 5 to 30 J.cm'2.

8. A method or use according to any preceding claim wherein the photosensitiser is present in or on the tissue, wound or lesion at a concentration of 0.00001 to 1% w/v.

9. A method or use according to any preceding claim wherein the photosensitiser is used in the form of a pharmaceutical composition comprising the photosensitiser in solution in a pharmaceutically acceptable aqueous carrier.

10. A method or use according to claim 9 wherein the pharmaceutical composition further comprises one or more accessory ingredients selected from buffers, salts for adjusting the tonicity of the solution, antioxidants, preservatives, gelling agents and remineralisation agents.